Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

February 1, 2027

Conditions

Palmoplantar Pustulosis

Interventions

DRUG

Deucravacitinib

25 subjects with palmoplantar pustulosis will be allocated to receive oral Deucravacitinib 6mg everyday for 16 weeks.

Trial Locations (1)

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Peking University First Hospital

OTHER

NCT07000630 - Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis | Biotech Hunter | Biotech Hunter